Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug ...
Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® ...
Pfizer Inc. PFE on Wednesday shared topline results from the late-stage study of its cancer treatment, ELREXFIO (elranatamab) ...
Pfizer said on Wednesday its drug Elrexfio met the main goal in a late-stage trial that tested the blood cancer treatment ...
Pfizer is navigating declining COVID-19 product sales and looming patent expirations by leaning on new drug launches, acquisitions, and a robust pipeline to sustain its 6.4% forward dividend yield.
Final analysis: Pfizer's COVID-19 vaccine 95% effective, company to seek authorization within 'days'
A final analysis of a COVID-19 vaccine candidate produced by Pfizer and BioNTech shows that the drug is 95% effective in preventing the coronavirus, and the companies say they hope to apply for ...
Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...
Key opportunities include capitalizing on rising screen time, increased demand for preservative-free & advanced formulations, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results